NCT04271592 - A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

May 17, 2020

Primary Completion Date

November 3, 2020

Study Completion Date

January 14, 2021

Conditions

Chronic Hepatitis B

Interventions

DRUG

ABI-H3733 Liquid Oral Dosage Form

ABI-H3733 liquid oral dosage form

DRUG

ABI-H3733 Solid Oral Dosage Form

ABI-H3733 solid oral dosage form

DRUG

Placebo to ABI-H3733 Liquid Oral Dosage Form

Placebo to ABI-H3733 liquid oral dosage form

DRUG

Placebo to ABI-H3733 Solid Oral Dosage Form

Placebo to ABI-H3733 solid oral dosage form

Trial Locations (1)

Auckland Clinical Studies, Auckland